Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

amyloid

- PMLiVE

CHMP backs Piramal’s Alzheimer’s imaging agent

Neuraceq recommended for approval in Europe

- PMLiVE

Interview: Mike Hutton, Lilly

Lilly’s chief scientific officer for neurodegenerative diseases talks about his hopes for Alzheimer’s research and making the move from academia to pharma

Eli Lilly HQ

Lilly exploring diabetes portfolio for Alzheimer’s potential

Undertakes pre-clinical investigations as it monitors the area

- PMLiVE

Takeda continues Actos resurrection as Alzheimer’s drug

Late-stage trial will see if pioglitazone can delay disease progression

- PMLiVE

Non-amyloid therapies emerging for Alzheimer’s at AAIC

AAIC meeting hears new clinical data from Lundbeck, Baxter, Chiesi and Takeda

- PMLiVE

Medicare puts brake on Lilly’s Alzheimer’s test

Will only reimburse new Alzheimer's diagnostic Amyvid for patients in trials

- PMLiVE

Merck taps Luminex for Alzheimer’s biomarker

Licenses companion diagnostic to use in its clinical trials

- PMLiVE

Pharma CEOs team up to tackle Alzheimer’s

Call for Global Alzheimer’s Action Plan to prevent and treat neurological condition by 2025

- PMLiVE

Lilly gets go-ahead for Alzheimer’s diagnostic in EU

Amyvid can detect amyloid plaques – a hallmark of the condition

- PMLiVE

Lilly plans another trial for Alzheimer’s hope solanezumab

Presses on with another late-stage study for the drug

Bristol-Myers Squibb (BMS) building

BMS ends development of Alzheimer’s candidate avagacestat

Amyloid-targeting candidate fails to make it to phase III trials

- PMLiVE

Merck & Co takes Alzheimer’s prospect into phase II/III trials

Developed to interrupt formation of amyloid plaques

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links